Clinical Trial Update: Clinical Study of Recombinant Novel Coronavirus（COVID-19） Vaccine (CHO Cell) Combined With Influenza Vaccine [Phase 3]

View source ↗

Summary

Phase 3 clinical trial of a recombinant COVID-19 vaccine (CHO cell) combined with influenza vaccine has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronavirus Disease 2019

Drugs mentioned

• Recombinant Novel Coronavirus (COVID-19) Vaccine (CHO Cell) Combined With Influenza Vaccine

Snippet

Sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Conditions: Coronavirus Disease 2019 | Phase 3 | Status: COMPLETED